Sign up to save your podcasts
Or
Share Is early use of biologic agents cost-effective in Crohn’s disease?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Is early use of biologic agents cost-effective in Crohn’s disease?
Fascinating results from Nadia Pillai, using real world data from a Swiss IBD cohort to model the cost-effectiveness of early biologic therapy. Early use of biologics is not cost effective in this cohort, but this outcome changes with biologic price drops or with more careful patient selection.
View all episodes
By Oxford University PressFascinating results from Nadia Pillai, using real world data from a Swiss IBD cohort to model the cost-effectiveness of early biologic therapy. Early use of biologics is not cost effective in this cohort, but this outcome changes with biologic price drops or with more careful patient selection.